PL363239A1 - Wyciszone przeciwciała anty-CD28 i ich zastosowanie - Google Patents

Wyciszone przeciwciała anty-CD28 i ich zastosowanie

Info

Publication number
PL363239A1
PL363239A1 PL01363239A PL36323901A PL363239A1 PL 363239 A1 PL363239 A1 PL 363239A1 PL 01363239 A PL01363239 A PL 01363239A PL 36323901 A PL36323901 A PL 36323901A PL 363239 A1 PL363239 A1 PL 363239A1
Authority
PL
Poland
Prior art keywords
silensed
antibodies
silensed anti
Prior art date
Application number
PL01363239A
Other languages
English (en)
Inventor
Yun J. Tso
Paul Hinton
Maximiliano Vasouez
Kouichi Tamura
Yasuyuki Higasji
Nobuo Seki
Hirotsugu Ueda
Original Assignee
Fuijsawa Pharmaceutical Co, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuijsawa Pharmaceutical Co, Ltd. filed Critical Fuijsawa Pharmaceutical Co, Ltd.
Publication of PL363239A1 publication Critical patent/PL363239A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL01363239A 2000-12-14 2001-12-14 Wyciszone przeciwciała anty-CD28 i ich zastosowanie PL363239A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14

Publications (1)

Publication Number Publication Date
PL363239A1 true PL363239A1 (pl) 2004-11-15

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01363239A PL363239A1 (pl) 2000-12-14 2001-12-14 Wyciszone przeciwciała anty-CD28 i ich zastosowanie

Country Status (18)

Country Link
EP (1) EP1341553A4 (pl)
JP (1) JP2004515243A (pl)
KR (1) KR20040020866A (pl)
CN (1) CN1272345C (pl)
AR (1) AR031924A1 (pl)
AU (2) AU2002226086C1 (pl)
BR (1) BR0116686A (pl)
CA (1) CA2432736A1 (pl)
CZ (1) CZ20031909A3 (pl)
HU (1) HUP0400697A3 (pl)
IL (1) IL156262A0 (pl)
MX (1) MXPA03005327A (pl)
NO (1) NO20032542L (pl)
NZ (1) NZ526569A (pl)
PL (1) PL363239A1 (pl)
RU (1) RU2261723C2 (pl)
WO (1) WO2002047721A1 (pl)
ZA (1) ZA200305384B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
WO2002066059A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc Agents that specifically block cd28-mediated signaling and uses therefor
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
FR2951176A1 (fr) 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
LT2536764T (lt) * 2010-02-18 2018-10-25 Ose Immunotherapeutics Anti-cd28 humanizuoti antikūnai
PT3528787T (pt) 2016-10-21 2026-03-11 Amgen Inc Formulações farmacêuticas e métodos para produzir as mesmas
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
CA3130348A1 (en) * 2019-03-14 2020-09-17 Motti HAKIM A method for immunosuppression
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
JP2023509803A (ja) 2019-12-02 2023-03-09 ビオンド バイオロジクス リミテッド Ｍｍｐ抑制の使用
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US12365743B2 (en) 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024148336A1 (en) * 2023-01-06 2024-07-11 Igm Biosciences, Inc. T cell costimulatory multimeric binding molecules and uses thereof
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28

Also Published As

Publication number Publication date
CA2432736A1 (en) 2002-06-20
ZA200305384B (en) 2004-10-11
EP1341553A1 (en) 2003-09-10
HUP0400697A2 (hu) 2004-06-28
AR031924A1 (es) 2003-10-08
CN1272345C (zh) 2006-08-30
WO2002047721A1 (en) 2002-06-20
RU2003121231A (ru) 2005-02-10
AU2002226086C1 (en) 2006-03-09
CN1489473A (zh) 2004-04-14
EP1341553A4 (en) 2004-07-28
RU2261723C2 (ru) 2005-10-10
CZ20031909A3 (cs) 2003-11-12
AU2002226086B2 (en) 2005-08-25
NO20032542L (no) 2003-08-07
NZ526569A (en) 2005-07-29
AU2608602A (en) 2002-06-24
IL156262A0 (en) 2004-01-04
KR20040020866A (ko) 2004-03-09
HUP0400697A3 (en) 2007-05-02
JP2004515243A (ja) 2004-05-27
NO20032542D0 (no) 2003-06-05
MXPA03005327A (es) 2004-12-03
BR0116686A (pt) 2003-12-30

Similar Documents

Publication Publication Date Title
AU2608602A (en) Silensed anti-cd28 antibodies and use thereof
TWI316088B (en) Anti-tnf alpha antibodies and their uses
IL151853A (en) Multivalent antibodies and uses thereof
GB0029360D0 (en) Humanised antibodies and uses thereof
EP1551447A4 (en) ANTI-ADDL ANTIBODIES AND USES THEREOF
IL154325A (en) Isolated anti-il-12 antibody and composition comprising the same
HUP0302128A3 (en) Anti-dual integrin antibodies, compositions, methods and uses
GB9927332D0 (en) Novel antibody and uses thereof
IL156161A0 (en) Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors
GB0007333D0 (en) Novel compounds and their manufacture and use
AU2003219093A8 (en) Anti-hpv-16 e7 antibodies and their use
IL172510A0 (en) Antibodies and uses thereof
IL166063A0 (en) Antibodies and uses thereof
GB0026134D0 (en) Peptides and their use
GB0007530D0 (en) Trityl-type compounds and their use
GB0021497D0 (en) Compounds and their use
GB0005071D0 (en) Antibodies
GB0003527D0 (en) Antibodies
GB0227080D0 (en) Antibodies and uses thereof
GB0002559D0 (en) Virulencegene and protein and their use
GB0016824D0 (en) Human monoclonal antibodies
GB0017139D0 (en) Human monoclonal antibodies
AU2002338089A1 (en) Antibody and use thereof
GB0026136D0 (en) Peptides and their use
GB0018148D0 (en) Peptides and their use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)